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The importance of regulatory T cells (Tregs) in balancing the effector arm of the immune
system is well documented, playing a central role in preventing autoimmunity, facilitating
graft tolerance following organ transplantation, and having a detrimental impact on the
development of anti-tumor immunity. These regulatory responses use a variety of mech-
anisms to mediate suppression, including soluble factors. While IL-10 and TGF-β are the
most commonly studied immunosuppressive cytokines, the recently identified IL-35 has
been shown to have potent suppressive function in vitro and in vivo. Furthermore, not only
does IL-35 have the ability to directly suppress effector T cell responses, it is also able to
expand regulatory responses by propagating infectious tolerance and generating a potent
population of IL-35-expressing inducibleTregs. In this review, we summarize research char-
acterizing the structure and function of IL-35, examine its role in disease, and discuss how
it can contribute to the induction of a distinct population of inducible Tregs.
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INTRODUCTION
The immune system has evolved to establish multiple layers of
defense against a variety of pathogens and diseases. However,
concurrent with these effector responses are a robust network of
regulatory responses that are able to keep the effector branch of
the immune system in check and ensure that they do not lead to
potentially harmful autoimmunity. These suppressive responses
are mediated by a myriad of cell types, including myeloid-derived
suppressor cells as well as macrophages with suppressive function
[such as tumor-associated macrophages (1)],but suppressive func-
tion is most commonly associated with regulatory T cells (Tregs).
T cells with potential suppressive activity were identified in the
seminal research by Gershon and Kondo as well as Nishizuka and
Sakakura more than 40 years ago, showing that lymphocytes can
suppress T cell responses and that this tolerance could be trans-
ferred into naive mice (2–5). However, after this foundational
work, research into Tregs went through a period of controversy
and conflicting results, with difficulty in identifying a molecular
basis for their suppressive function leading some to question their
existence. Following more than a decade of studies aimed at elu-
cidating the mechanisms that mediate Treg activity, interest was
rekindled in the mid-1990s with the transformational research of
Sakaguchi and colleagues, who specifically identified a population
of CD4+CD25+T cells that had suppressive function, which were
coined as naturally occurring thymic-derived Tregs, or natural
Abbreviations: APC, antigen-presenting cell; DC, dendritic cell; EAE, experimental
autoimmune encephalitis; Ebi3, Epstein–Barr virus-induced gene 3; IL, interleukin;
iTreg, induced regulatory T cell; NIMA, non-inherited maternal antigen; NK, nat-
ural killer; nTreg, natural regulatory T cell; PAP, prostatic acid phosphatase; TGF,
transforming growth factor; Treg, regulatory T cell.
Tregs (nTreg) (6). These Tregs were later identified as also express-
ing the intracellular transcription factor Foxp3, and were found
to mediate suppression against a wide array of effector immune
responses, including CD4+ and CD8+T cells,B cells,natural killer
(NK), and NK-T cells, and even inducing dendritic cells (DCs) and
macrophages into a more tolerogenic phenotype. However, while
nTregs play a central role in mediating tolerance to a variety of self
antigens, they are recognized as not being the primary mediator
of tolerance to pathogens and other antigens encountered in the
periphery. This role belongs to a broad class of cells classified as
peripherally derived or inducible Tregs (iTregs), which are CD4+
or CD8+ T cells which enter the periphery as naive T cells but
encounter their antigen under conditions which are not conducive
to the generation of productive effector responses, such as envi-
ronments rich in immunosuppressive cytokines such as TGF-β.
When activated in these conditions, iTregs gain potent suppressive
functions, inhibiting T-cell proliferation and effector functions in
an antigen non-specific fashion, and play a central role in mediat-
ing regulation and propagating infectious tolerance in a variety of
malignancies, including infectious diseases and cancer.
Inducible Tregs are further divided into subclasses of iTregs,
which are classified based largely on the mechanisms they use to
mediate regulation (though the functional mechanisms of sup-
pression utilized by these various iTregs are not strictly limited to
each subpopulation – for example, multiple iTreg populations use
surface molecules such as CTLA-4 or PD-1 to mediate infectious
tolerance). Tr1 induced regulatory cells mediate suppression pri-
marily through the secretion of the immunosuppressive cytokine
IL-10, and are further characterized by their lack of Foxp3 and
CD25 expression which are expressed by nTregs (7). The sec-
ond class of iTregs are Th3 cells, which were one of the earliest
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populations of Tregs and were identified as playing a role in medi-
ating tolerance in experimental autoimmune encephalitis (EAE).
These cells express CD25 and Foxp3 and predominantly utilize
TGF-β to mediate suppression, with minimal expression of IL-4
and IL-10 (8).
While the Tr1 and Th3 populations of iTregs were long con-
sidered to be the only defined induced regulatory populations,
research has identified another population of induced Tregs that
can are potent mediators of suppression as well as in the propaga-
tion of infectious tolerance: iTr35 regulatory cells. These inducible
regulatory cells were identified by Dario Vignali and colleagues
and mediate suppression primarily through the expression of
the regulatory cytokine IL-35 (9). In this review, we will discuss
the identification and characterization of IL-35, how it medi-
ates suppression, the role it has been shown to play in disease,
and the importance of IL-35 and more specifically iTr35 cells in
propagating infectious tolerance.
IL-35: COMPOSITION, SIGNALING, AND EXPRESSION
Interleukin 35 belongs to the IL-12 family of cytokines, which is
a group of heterodimeric cytokines that are composed of one of
five subunits [p19, p28, p35, p40, and Epstein–Barr virus-induced
gene 3 (Ebi3)] that come together in various combinations to
form IL-12, IL-23, IL-27, and IL-35, as illustrated in Figure 1A
(10). Despite their shared components, these cytokines run the
spectrum of immunological effector functions. IL-12 is a pro-
inflammatory cytokine that is closely associated with the acti-
vation of Th1 immune responses. It is predominantly expressed
by monocytes and DCs, and its expression can be triggered by
activated T cells. The inflammatory activity of IL-12 is clearly
seen in efforts to target its activity in a variety of diseases.
In patients with malignancy, research has shown that recombi-
nant IL-12 can elicit anti-tumor responses in vivo (11). Alterna-
tively, efforts to inhibit the inflammatory effects of IL-12 have
been developed, including IL-12-blocking antibodies used to treat
autoimmune disorders such as EAE, where it has been shown
to prevent uncontrolled immune responses (12, 13). Similar to
IL-12, IL-23 also has inflammatory activity and can drive Th1
responses, as well as promoting the activity of NK and Th17
cells (14). As opposed to IL-12 and IL-23, IL-27 has a wide
range of immunomodulatory activities. While it can promote
Th1 development, IL-27 can also inhibit Th2 responses and
promote the suppression of T-cell responses depending on the
microenvironment (15).
FIGURE 1 | IL-12 family members and signaling pathways.
(A) Diagram showing the subunits that form the heterodimeric IL-12
family of cytokines, the subunits that form their receptors, and the
predominant STAT molecules that transmit their signals. (B) Diagram
showing the potential receptor and signaling pathways utilized by IL-35,
which can signal through gp130 or IL-12Rβ2 homodimers, or through a
unique gp130:IL-12Rβ2 heterodimer, which results in the formation of a
novel STAT1:STAT4 heterodimer that has distinct effects on target cells:
maximal suppression, IL-35 expression, and their conversion into iTr35
regulatory T cells.
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While IL-12, IL-23, and IL-27 can all play a role in promot-
ing inflammatory immune responses, the youngest member of
the IL-12 family, IL-35, is a purely immunosuppressive cytokine.
IL-35 was identified in the mid-2000s, first reported by Dario Vig-
nali and colleagues, and was soon after reported by his group
and others to be a potent mediator of suppression (9, 16). IL-
35 is a heterodimer composed of the p35 and Ebi3 subunits,
which were both identified as being over-expressed by Tregs and
not effector cells (9). The potential of these two subunits com-
ing together to form a novel heterodimer was first described in
1997 by Devergne and colleagues, who found that cells transfected
with p35 and Ebi3 lead to the secretion of a p35-Ebi3 heterodimer
(17). In this report, it was suggested that given the expression of
Ebi3 in many tissues replete with immune cells, it was likely that
this heterodimer had immunomodulatory function – however,
no functional studies were conducted for another 10 years. Recent
studies into the formation of this heterodimer found that subunits
from human and mouse can bind to the opposite species, indicat-
ing that the protein-protein interactions that form IL-35 are novel
to the IL-12 family and conserved between species (18). Further-
more, the protein binding sites were unique when compared to
those used for IL-12 and IL-27, and that no single mutation could
disrupt this interaction (18). This is particularly significant, as the
design of therapeutic interventions aimed at targeting the suppres-
sive activity of IL-35 could focus on small-molecule inhibitors of
this interaction which would selectively target IL-35 while leaving
IL-12 and IL-27 unaffected.
In addition to having a unique function when compared to
the other IL-12 family members, IL-35 is also unique in that
rather than being expressed primarily by antigen-presenting cells
(APCs), IL-35 is expressed primarily by Tregs. Since it was iden-
tified in 2007, dozens of reports have been published describing
IL-35 expression in both thymus-derived and peripheral Tregs.
This includes a subset of CD4+CD25+Foxp3+nTregs in humans,
mice, and even pigs (9, 19, 20), though this expression is thought to
occur only in a subset of IL-35+nTregs and is not constitutive (21).
Research has also identified expression of IL-35 in a population of
IL-35-induced CD4+Tregs, defined as iTr35 cells (22). In addition
to CD4+ Tregs, IL-35 has also been shown to be expressed and
mediate antigen-specific suppression in a population of CD8+
Tregs in patients with prostate cancer (23). Interestingly, other
non-immune cell types have also been shown to express IL-35,
including tumor cells (24, 25) and potentially an even broader
tissue expression profile in the course of inflammation (26). How-
ever, in all of these cell types, it has been noted that IL-35 expression
is minimal in unactivated T cells – rather, these cells need to
become activated for the induction of IL-35, such as through
engagement of their T-cell receptor or following inflammation
(19, 22, 26). This suggests that IL-35 may be more associated with
the suppressive activity of Tregs in peripheral tissues rather than
a constitutive marker of Tregs. The suggested expression of IL-35
by multiple cells types, including both natural and induced Treg,
emphasizes the need to further characterize the mechanisms that
regulate the expression of IL-35 in these populations.
After being expressed and secreted by Tregs, IL-35 then acts on
its target cells following binding to the IL-35 receptor. However,
as is the case with the subunits that make up the IL-12 family of
heterodimeric cytokines, the receptors for the IL-12 family are also
composed of five different subunits: IL-12Rβ1, IL-12Rβ2, IL-23R,
WSX, and gp130 (as illustrated in Figure 1B). The IL-35 recep-
tor is composed of IL-12Rβ2 and gp130, which are also associated
with the IL-12 and IL-27 receptors, respectively (27, 28). Following
binding of IL-35 to its receptor, its signal is transduced through
STAT1 and STAT4, which can also form a unique heterodimer and
result in the expression of target genes including p35 and Ebi3,
resulting in a feedback loop promoting increased IL-35 expression
(28). However, IL-35 is also unique from the other members of
the IL-12 family in that it can also signal through a homodimer
of its receptor subunits. However, when IL-35 binds to one of its
homodimeric receptors, only one branch of its signal transduc-
tion pathway is activated (either STAT1 or STAT4 for gp130:gp130
or IL-12Rβ2:IL-12Rβ2 homodimers, respectively), resulting in a
partial loss of the suppressive activity of IL-35 compared with sig-
naling through the fully functional IL-12Rβ2-gp130 heterodimer
receptor, as diagramed in Figure 1B (28). The use of these sub-
units sheds some light onto the target of IL-35 activity; gp130 is
expressed in most cell types (29), whereas IL-12Rβ2 is expressed
predominantly on activated T cells, NK cells, and to a lesser extent
DCs and B cells (30).
IL-35: MECHANISMS OF SUPPRESSION AND ROLE IN
DISEASE
Since its discovery, the predominant mechanism of suppression
associated with the activity of IL-35 is its ability to suppress T-cell
proliferation and effector functions. Foundational work into the
activity of IL-35 utilized IL-12a−/− and Ebi3−/−mice, finding that
CD4+ Treg lacking IL-35 expression had a significantly reduced
ability to suppress T-cell proliferation (9), an observation that has
been repeated in numerous models by several groups (19, 22, 31–
33). The ability of IL-35 to suppress T-cell responses has also been
clearly illustrated in studies using recombinant IL-35 (rIL-35),
where it can decrease T-cell proliferation as well as T-cell cytokine
expression, though these studies have been somewhat complicated
by the difficulty in generating an active heterodimeric form of IL-
35 (9, 16, 34, 35). In related studies, the ectopic expression of
IL-35 by conventional CD4+ T cells (using a transfected IL-35
expression construct) results in these conventional T cells gaining
a regulatory phenotype, manifested by the ability to potently sup-
press T-cell proliferation (9, 22). The suppressive activity of IL-35
is not limited to CD4+ Tregs, as a population of CD8+CTLA-4+
Tregs was also found to suppress the proliferation of autologous T
cells in a contact-independent, IL-35-dependent fashion (23).
While mechanistic studies into IL-35 have focused on its abil-
ity to suppress CD4+ and CD8+ T-cell proliferation, IL-35 has
also been shown to have a role in suppressing Th17 responses.
Tregs expressing IL-35 have been shown to inhibit the differenti-
ation of CD4+ T cells into Th17 effector cells, and mice lacking
Ebi3 have a significant increase in the production of IL-17 (32,
36–38). This has also been reproduced in studies using rIL-35, in
which treatment with rIL-35 reduces Th17 differentiation as well
as the function of Th17 cells (16, 34). In addition to its effects
on Th17 immunity, one report has even suggested that rIL-35 can
lead to decreased antibody titers (34). While this is the only report
to our knowledge to associate IL-35 activity with the suppression
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of humoral immunity, it has significant implications toward the
precise mechanism of action of IL-35. While in vitro studies have
clearly shown that IL-35 is able to directly act on effector T cells
(supported by the expression profiles of the IL-35 receptor sub-
units), the ability of IL-35 to suppress antibody responses could
suggest that IL-35 is also able to act on other cell populations,
though it could also be a reflection of the inhibition of helper T
cell responses that contribute to humoral immunity.
Given the direct suppressive activity of IL-35, there has been
interest in evaluating the role that IL-35 can play in the devel-
opment of a variety of diseases (summarized in Table 1). Several
diseases have been shown to be associated with increased IL-35
expression, including multiple inflammatory diseases, coronary
artery disease, and cancer. In individuals with acute myeloid
leukemia, the development of disease has been shown to be asso-
ciated with elevated plasma levels of IL-35 (39). This has been
supported by results in lung cancer, where a study evaluating Ebi3
levels in lung cancer patients found that Ebi3 levels are elevated
in patients with malignancy, predicts for poor outcome, and is an
independent prognostic indicator of disease (although this study
only examined Ebi3, and not the p35 subunit of IL-35) (40). Addi-
tionally, in murine models of melanoma and colorectal carcinoma,
the establishment of tumors has been shown to lead to increased
IL-35 expression in CD4+ tumor-infiltrating lymphocytes, which
are subsequently able to suppress T-cell proliferation (22). This
likely contributes to the inhibition of the anti-tumor effects of
adoptively transferred CD4+ and CD8+ T cells in this melanoma
model.
The loss of IL-35 has also been shown to be associated with the
development and exacerbation of disease, including many inflam-
matory diseases such as encephalomyelitis and inflammatory
bowel disease (Table 1). In multiple models of encephalomyelitis,
wild-type Tregs can prevent the onset and severity of disease.
However, animals that lack functional IL-35 were shown to have
enhanced inflammatory immune responses and increased disease
(9, 32, 33). Similar observations have been shown in inflammatory
bowel disease, liver fibrosis, and models of lethal autoimmune dis-
ease (9, 22, 35, 38). Conversely, given that the loss of IL-35 is
associated with increased incidence and severity of inflammatory
diseases, the induction of IL-35 expression has been shown to
alleviate a variety of disease symptoms (Table 1). In models of
inflammatory bowel disease, IL-35 gene therapy and the adoptive
transfer of IL-35-expressing Tregs have been shown to cure coli-
tis symptoms (22, 35). The same holds true in collagen-induced
arthritis, where rIL-35 reduces the frequency and severity of arthri-
tis and a decrease in inflammatory immune responses (16, 34).
As opposed to these inflammatory diseases, tumor models have
shown that IL-35 contributes to tumorigenesis (22, 25). These
effects are mediated through both immune-directed and tumor-
directed effects, as IL-35 can act to suppress tumor-infiltrating
lymphocytes that may have anti-tumor activity, as well as poten-
tially supporting the proliferation of tumor cells by promoting
angiogenesis (22, 25).
While the direct suppressive activity of IL-35 has been estab-
lished in numerous reports in vitro and in vivo, research into
immune tolerance has shown that the low frequency of individ-
ual regulatory populations alone are largely insufficient to control
effector immunity. Therefore, to expand the breadth of suppressive
immunity, Tregs are able to induce and mobilize additional regu-
latory immune cells. This concept of infectious tolerance is central
to the ability of the immune system to maintain tight control of
effector responses, whereby Tregs can transfer suppressive func-
tion onto a nominally conventional T cell population. Suppressive
cytokines play a central role in the propagation of infectious toler-
ance, including IL-35, which has been shown to play an important
role in the expansion of regulatory immunity.
ROLE OF IL-35 IN PROPAGATING INFECTIOUS TOLERANCE
The concept of infectious tolerance was first proposed by Gershon
and Kondo in the early 1970s, where they showed that, “tolerance
. . . can be spread from one cell to another” (4). This was fur-
ther elucidated by Benjamin and Waldmann, who used antibodies
blocking T cell populations to induce tolerance to skin grafts (46),
and later in elegant studies by Qin and colleagues from the same
group, who used congenically marked T cells to show that suppres-
sive activity can be transferred from one cell population to another
(47). As additional molecular data regarding the suppressive mech-
anisms of Treg has become available, it has become clear that Tregs
can secrete cytokines that can induce naïve and even effector T cells
to gain a regulatory phenotype. This can occur by directly targeting
effector T cells and causing them to gain a suppressive phenotype,
as well as targeting DC populations and causing them to promote
the conversion of effector cells into regulatory cells (48). The most
commonly thought of cytokines involved in this conversion are
Treg-produced IL-10 and TGF-β, which can drive the generation
of Tr1 and Th3 cells, respectively. However, the ability to transmit
infectious tolerance is also a characteristic of IL-35, the produc-
tion of which can cause the conversion of conventional effector
T cells into induced regulatory cells that are potent mediators of
suppression in vitro and in vivo.
Some of the earliest reports of IL-35 began to shed light on
the potential role of this cytokine in infectious tolerance. In
a report by Niedbala and colleagues in 2007, they found that
a rIL-35 fusion protein induced the proliferation of a popula-
tion of CD4+CD25+Foxp3+ T cells, and which expressed IL-10
and suppressed T-cell proliferation in vitro (16). Additionally, in
another report utilizing a recombinant single-chain IL-35, it was
found that treatment of mice with rIL-35 resulted in a significant
increase in IL-10 (but not TGF-β) production by CD4+ T cells
in draining lymph nodes (34). When these mice were examined
further for the impact of IL-35 on Treg function, they found that
administration of IL-35 led to an increase in the frequency of
CD4+CD39+ Tregs that expressed Foxp3 and IL-10, and that IL-
35 promoted the proliferation of these T cells (34). Furthermore,
when these CD4+CD39+ T cells were adoptively transferred they
could protect animals from collagen-induced arthritis in an IL-10-
dependent fashion (34). These data together suggest that IL-35 is
able to promote the expansion of IL-10 producing iTregs, and that
these Tregs are able to mediate suppression in vitro and in vivo.
While these studies provided the earliest evidence that IL-35
could play a role in the propagation of infectious tolerance, it
remained unclear whether this induced regulatory population also
expressed IL-35, or whether IL-35 played any role in mediating
suppression in these induced regulatory cells. This was addressed
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Table 1 | Role of IL-35 on disease.
Disease/model Method of IL-35 detection Effects of disease on IL-35 expression Reference
STUDIES EVALUATING EFFECTS OF DISEASE ON IL-35 EXPRESSION
Acute myeloid
leukemia
ELISA Patients with AML have significantly higher plasma levels of IL-35
than healthy donors
Wu et al. (39)
Allergic airway
disease
qPCR Induction of allergic airway disease leads to increased Treg that
express IL-35
Whitehead et al.
(37)
Colorectal
carcinoma
qRTPCR Tumor injections lead to increase in IL-35 expression in
tumor-infiltrating CD4+T cells (CD4+Foxp3+ and CD4+Foxp3−)
Collison et al. (22)
Coronary artery
disease
ELISA Decreased IL-35 correlates with increased left ventricular ejection
fraction
Lin et al. (41)
Lung cancer Immunohistochemistry and ELISA Lung cancer patients have significantly elevated serum levels of
Ebi3, and elevated Ebi3 expression correlates with poor prognosis,
and is an independent prognostic factor of disease
Nishino et al. (40)
Melanoma qRTPCR, Western blot Tumor injections lead to increase in IL-35 expression in
tumor-infiltrating CD4+T cells (CD4+Foxp3+ and CD4+Foxp3−),
which can suppress T-cell proliferation
Collison et al. (22)
Smoking-induced
lung inflammation
ELISA Animals exposed to cigarette smoke and treated with erythromycin
have increased levels of IL-35 in bronchoalveolar lavage fluid
Bai et al. (42)
Trichuris muris
infection
qRTPCR Infection withTrichuris muris induces significant increase in IL-35
expression in intestinal Tregs
Collison et al. (22)
Disease/model Mechanism of IL-35 expression Effects of IL-35 expression on disease Reference
STUDIES EVALUATING EFFECTS OF IL-35 ON DISEASE
Allergic airway
disease
Gene therapy using plasmid DNA
encoding single-chain IL-35 fusion
protein
IL-35 gene therapy decreases allergic airway inflammation and
inflammation-associated antibody responses
Huang et al. (43)
Autoimmune
diabetes
Ectopic expression of rIL-35 in
non-obese diabetic (NOD) mice
IL-35 expression protects animals from autoimmune diabetes by a
decrease in T-cell infiltration and proliferation (via G1 arrest)
Bettini et al. (44)
Cancer Ectopic expression of IL-35 in
murine tumor cell lines
IL-35 expression increases tumorigenesis by increasing infiltration
of CD11b+Gr1+ myeloid cells and thus increasing tumor
angiogenesis, as well as a decrease in the numbers and effector
functions of CD4+ and CD8+TIL
Wang et al. (25)
Collagen-induced
arthritis (CIA)
Intraperitoneal injection of
single-chain rIL-35
IL-35 reduces incidence, intensity, and progression of CIA, a
reduction of CIA-specific antibodies, a reduction of Th1 and Th17,
and protective CD4+CD39+CD25−Tregs
Kochetkova et al.
(34)
Collagen-induced
arthritis (CIA)
Intraperitoneal injection of rIL-35 IL-35 induces a significant reduction in the incidence and intensity of
CIA
Niedbala et al.
(16)
Inflammatory
bowel disease
Adoptive transfer of iTr35 cells into
IBD-bearing Rag1−/− mice
iTr35 cells cure inflammatory bowel disease Collison et al. (22)
Inflammatory
bowel disease
Gene therapy using plasmid DNA
encoding single-chain IL-35 fusion
protein
IL-35 gene therapy decreases symptoms of colitis and decrease in
colonic inflammatory markers
Wirtz et al. (35)
Lyme arthritis Subcutaneous injection of rIL-35 rIL-35 enhances Lyme arthritis in Borrelia-infected and -vaccinated
mice
Kuo et al. (45)
Melanoma Adoptive transfer of iTr35 cells into
tumor-bearing Rag1−/− mice
iTr35 cells suppress anti-tumor responses generated following
adoptive transfer of CD4+ and CD8+T cells
Collison et al. (22)
(Continued)
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Table 1 | Continued
Disease/model Transgenic mouse model Effects of knock-out on disease Reference
STUDIES EVALUATING EFFECTS OF IL-35 KNOCK-OUT ON DISEASE
Allergic airway
disease
Ebi3−/− mice Ebi3 is required for control of airway inflammation Whitehead et al.
(37)
Coronavirus-
induced
encephalomyelitis
Ebi3−/− mice Ebi3−/− mice have an increased viral load and increased mortality,
increased T cell and macrophage infiltration, and enhanced
viral-specific T-cell responses
Tirotta et al. (33)
Experimental
autoimmune
encephalomyelitis
(EAE)
Ebi3−/− mice nTreg or iTr35 cells, but not iTRcon or Ebi3−/− iTr35 cells, prevent
severity of EAE
Collison et al. (22)
Experimental
autoimmune
encephalomyelitis
(EAE)
Ebi3−/− mice Ebi3−/− mice have marginally increased EAE, and significantly
increased Th1 and Th17 responses
Liu et al. (32)
Homeostatic
expansion
Ebi3−/− mice Adoptive transfer of iTr35, but not iTr35 cells lacking IL-35 expression
(Ebi3−/− mice or WT mice given IL-35 blocking antibody), cells can
prevent homeostatic expansion
Collison et al. (22)
Inflammatory
bowel disease
IL-27p28−/− and Ebi3−/− mice Ebi3-deficient mice have increased colitis, shorter survival, and
increased expression of inflammatory markers (not seen in
IL-27p28 -deficient mice)
Wirtz et al. (35)
Inflammatory
bowel disease
Ebi3−/− and IL-12a−/− mice Transfer of Treg cures inflammatory bowel disease, but not Treg that
lack either Ebi3 or IL-12a
Collison et al. (9)
Lethal
autoimmunity
Ebi3−/− and IL-12a−/− mice Adoptive transfer of nTreg or iTr35 cells can prevent lethal
autoimmunity, but iTr35 cells lacking Ebi3 or IL-12a could not prevent
autoimmunity
Collison et al. (22)
Liver fibrosis IL-12p35−/− and IL-12p40−/− mice IL-12p35−/− mice (but not IL-12p40−/− mice) have increased liver
inflammation, bile duct damage, and development of Th17
responses
Tsuda et al. (38)
in an expansive report from by Collison and colleagues in late
2010 that not only specifically studied the role that IL-35 plays
in the conversion of conventional T cells into induced Tregs, but
also evaluated the role that IL-35 has in mediating the suppressive
function of these iTreg (22). In this report, they show that treating
either human or mouse conventional CD4+Foxp3− T cells with
IL-35 causes these T conv to begin to express IL-35 (but not IL-10
nor TGF-β), and that these T conv cells can then suppress T-cell
proliferation in a contact-independent fashion. Further support-
ing the lack of a role for IL-10 and TGF-β, blocking either of these
cytokines did not affect the suppressive function of these cells
whereas blocking IL-35 significantly abrogated this suppression,
suggesting that these IL-35-induced regulatory cells represented
a novel population of iTregs rather than the conventional Tr1 or
Th3 cells, which they defined as iTr35 cells.
The conversion of conventional T cells into an IL-35-expressing
inducible Treg was also shown to occur when T conv were cultured
with nTreg, which have been shown to express higher levels of IL-
35 when cultured with conventional T cells (49). When mouse
nTreg were cultured with T conv cells, the T conv cells began to
express IL-35 and were then able to suppress T-cell proliferation
(22). Interestingly, this conversion was found to require IL-35 and
IL-10 expression by nTregs; however, once these T conv cells had
gained a regulatory phenotype, IL-10 was not required for their
suppressive activity. In a later report, the same group confirmed
that this conversion of T conv into IL-35-expressing iTregs occurred
in a contact-independent fashion through the activity of IL-35,
but did not require IL-10 nor TGF-β (19). Furthermore, in this
report they also show that maximal Treg suppression requires not
only IL-35 expression but also contact with T conv that can sub-
sequently be converted into iTr35 cells (19), further highlighting
the importance of infectious tolerance in the overall suppressive
activity of IL-35.
The generation of iTr35 cells has also been shown to occur nat-
urally following the onset of various diseases. In one model, mice
were infected with an intestinal parasite that induces an inflam-
matory response followed by the expansion of Treg responses in
the intestine. Following this infection, CD4+ Foxp3+ nTregs in
the spleen were found to have negligible levels of IL-35 expression,
whereas CD4+Foxp3+ at the site of infection had a significant
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increase in IL-35 (22). Interestingly, when CD4+Foxp3− con-
ventional T cells were examined for IL-35, negligible levels were
found in the spleen, whereas CD4+Foxp3− T cells at the infection
site had a significant increase in IL-35 expression (22). Simi-
lar results were observed in two different tumor models (MC38
colorectal and B16 melanoma tumor cell lines), where tumor inoc-
ulation led to an increase in IL-35 expression in CD4+Foxp3+ and
CD4+Foxp3−T cells that infiltrated the tumor, whereas there was
negligible IL-35 expression in splenic T cells (22). Furthermore,
these tumor-infiltrating CD4+Foxp3− T cells were able to sup-
press T-cell proliferation in vitro in an IL-35-dependent fashion,
indicating that tumor establishment led to the generation of iTr35
cells (22).
The observation that tumor formation leads to the genera-
tion of iTr35 cells suggests that these cells may play a role in
promoting tumor development, a characteristic that is associated
with other induced Treg populations. In a variety of malignan-
cies, increased frequencies of Tregs has been shown to correlate
with a poor prognosis for patients, though this observation is not
absolute (50). The profoundly suppressive tumor microenviron-
ment has been shown to promote the generation of regulatory
immune responses, using factors such as TGF-β or adenosine to
mediate the conversion of effector lymphocytes into iTregs (51,
52). Furthermore, these tumor-infiltrating iTreg have been shown
to have greater suppressive activity that nTreg, both in terms of the
levels of suppression as well as the mechanisms used (22, 53–55).
However, this does not appear to be the case with IL-35, as tumor-
infiltrating CD4+Foxp3+ nTregs had higher levels of suppression
then infiltrating Foxp3− iTr35 cells (22). This likely reflects the
multitude of suppressive mechanisms that nTreg are able to uti-
lize to mediate suppression, as tumor-infiltrating Ebi3−/− nTreg
were able to suppression T-cell proliferation at equal levels com-
pared with wild-type nTreg (22), and even Treg that lack both IL-35
and IL-10 expression can still mediate suppression through factors
such as TRAIL (56). However, iTr35 cells appear to lack this func-
tional plasticity, as Ebi3−/− mice do not have tumor-infiltrating
induced regulatory cells with suppressive function, and iTr35 cells
lacking Ebi3 and/or IL-12p35 lack efficacy in preventing autoim-
mune responses in a variety of models in addition to these tumor
models (22).
Despite this requirement for IL-35, iTr35 cells, and the role
of IL-35 expression on the propagation of infectious tolerance is
an important component of the suppressive tumor microenvi-
ronment. When Rag1−/− mice are challenged with tumors and
then receive adoptively transferred wild-type CD4+ and CD8+
T cells, these T cells are able to mediate an anti-tumor response
and keep tumor growth in check (22). When wild-type Tregs are
transferred as well, the tumors grow rapidly, reflecting the abil-
ity of Treg to suppress the anti-tumor response associated with the
transfer of the CD4+ and CD8+T cells, both by directly suppress-
ing T-cell proliferation as well as converting these conventional T
cells into regulatory cells (22). However, when tumor-bearing ani-
mals receive an adoptive transfer containing wild-type CD8+ T
cells and Ebi3−/− CD4+ T cells, the growth of these tumors was
reduced by approximately 50% (22). This suggests that the con-
version of T conv into iTr35 cells is a significant contributor to
the suppression of anti-tumor immunity, and that the therapeutic
targeting of this regulatory population could promote anti-tumor
responses.
The dependence of iTr35 cells on IL-35 also suggests that these
cells may have different characteristics regarding their long-term
phenotypic and functional stability. Given the nature of induced
regulatory cells, which gain or lose immunosuppressive activity
depending on the microenvironment in which they are activated,
the stability of these induced populations is thought to be tran-
sient. However, data regarding the stability of iTr35 cells in vivo
suggests otherwise. In numerous models, the transfer of iTreg was
shown to mediate clinical efficacy for several weeks following a
single adoptive transfer, suggesting that these cells retain their
suppressive function for an extended period of time (22). Further-
more, when congenically marked iTr35 or Th3 cells were injected
into mice and recovery was measured over time, it was found
that 33% of the injected iTr35 cells were recoverable after 1 week,
30% after 2 weeks, and 20% after more than 3 weeks, compared
with only 12% of Th3 cells that were recovered 1 week following
transfer (22). Additionally, these cells retained their suppressive
function; even 25 days following injection, adoptively transferred
iTr35 cells were able to suppress T-cell proliferation at the same
levels as freshly isolated iTr35 cells, whereas Th3 cells had signifi-
cantly reduced suppressive function (22). This suggests that iTr35
cells may represent more of a terminally differentiated regulatory
population, and rely on the potent suppressive activity of IL-35 to
mediate suppression. However, further work is necessary to char-
acterize these iTr35 cells, and other suppressive mechanisms that
they may gain or lose over time.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
As we look toward the future of immune regulation and infectious
tolerance, it is essential to focus not only on identifying novel
mediators of tolerance, but how these populations can be reli-
ably identified. This is particularly relevant with the generation
of induced Tregs during the propagation of infectious tolerance,
as the plastic nature of these populations makes them challeng-
ing to identify and track over time. Even iTr35 cells, which may
represent more of a stable regulatory population than Tr1 or Th3
cells, are incredibly challenging to identify. While these cells are
predominantly identified based on their robust expression of IL-
35, the detection of IL-35 expression can be daunting. The nature
of the IL-12 family of cytokines requires the expression of all five
subunits to be interrogated to ensure that it is IL-35 that is being
expressed by a putative regulatory population (even though Tregs
do not express significant levels of the other IL-12 family mem-
bers). This is also manifested in difficulty detecting IL-35 protein
levels using current commercially available reagents and the lack
of an antibody that jointly recognizes a conformational epitope
from IL-35, thus requiring Ebi3, p35, and the other IL-12 subunits
to be examined. Additionally, the difficulty in generating function-
ally active rIL-35 also delayed research and led to the necessity of
multiple levels of evaluation in studying the suppressive effects of
IL-35. As these reagents are developed and become commercially
available, it is to be hoped that increased research into IL-35 will
better define and characterize Tregs that express this cytokine.
While IL-35 expression can be analyzed on fixed or lysed cell
populations, what would be ideal would be a series of cell surface
www.frontiersin.org October 2013 | Volume 4 | Article 315 | 7
Olson et al. Propagation of infectious tolerance by IL-35
markers that can be used to identify iTr35 cells, allowing these
cells to be isolated and further characterized. Currently, iTr35 cells
are characterized only by their expression of CTLA-4 and CD25,
as well as a lack of intracellular Foxp3; however, a gene microar-
ray comparing iTr35 cells with conventional Treg found that there
was no significant genetic signature that could be used to distin-
guish one regulatory population from the other (22). Furthermore,
while treatment with rIL-35 was shown to induce a population of
CD4+CD39+CD25− Tregs that express IL-10, these cells were
not evaluated for expression of IL-35, causing CD39 to remain
one of the potential markers of iTr35 cells, though its expression is
clearly not restricted to iTr35 cells (34). This highlights the impor-
tance of elucidating markers for iTr35 cells that have not yet been
evaluated [such as GITR, PD-1, CD127, or even HELIOS, whose
expression is traditionally associated with nTreg but was recently
suggested to also be present on iTreg (57, 58)] that can facilitate
the identification of iTr35 cells without expression analysis.
As clearly illustrated in Table 1, IL-35 plays an important
role in a variety of diseases. Furthermore, research from our
group has identified that IL-35-expressing Tregs also play a cen-
tral role in mediating tolerance in transplantation tolerance,
immune responses to non-inherited maternal antigens (NIMAs),
and prostate cancer [Ref. (23); and Olson et al., unpublished
results], which we also found were dependent on the expression of
CTLA-4. Interestingly, when we examined collagen type V-specific
regulatory responses, we did not find a role for IL-35 [contrary to
results obtained from other groups (16, 34)] nor CTLA-4, though
we did find that these responses relied heavily on TGF-β. This
suggests that the regulatory responses we identified in the trans-
plant, NIMA, and prostate cancer patients may have been relying
on iTr35 cells, whereas the responses we identified to collagen
V were nTregs, and suggests that potentially CTLA-4 and IL-35-
dependency may be a technique that can be used to identify this
population of inducible regulatory cells.
In our research evaluating the role of IL-35 expression in
antigen-specific tolerance in prostate cancer patients, we identified
CD8+CTLA-4+ IL-35-expressing T cells specific for the prostate
tumor-associated antigen prostatic acid phosphatase (PAP), which
were present in some patients with prostate cancer (23). Imme-
diately following immunization with a DNA vaccine targeting
PAP, these antigen-specific CD8+CTLA-4+ T cells prevented the
detection of concurrent PAP-specific effector responses; how-
ever, in long-term follow ups, we found that PAP-specific effector
responses could be detected in these individuals. These results
raise questions regarding the nature of these CD8+CTLA-4+
IL-35-expressing regulatory cells; in particular, whether they rep-
resent a population of CD8+ T cells that have been induced in
the periphery to gain IL-35 expression and suppressive activity,
or alternatively if they are an antigen-specific thymus-derived
population of nTregs. If these PAP-specific CD8+ regulatory
responses represent a population of nTreg cells, their presence in
the periphery and tumor microenvironment pre- and immediately
post-immunization would suppress and prevent the detection
of PAP-specific effector responses (as well as potentially induce
the generation of IL-35-expressing Tregs), whereas the long-term
generation and expansion of effector responses could eventually
outnumber these suppressive responses and ultimately lead to
the desired goal: the generation of productive, antigen-specific
anti-tumor immunity (Figure 2A). Alternatively, if these PAP-
specific CD8+ regulatory cells represent an induced population
of CD8+ iTr35 cells, then their presence pre-immunization would
be able to convert antigen-specific effector responses into addi-
tional regulatory responses (thus furthering the propagation of
infectious tolerance) until extended period following immuniza-
tion when effector responses overcome these regulatory responses,
either by simply outnumbering regulatory CD8 T cells or by pre-
venting the conversion of effector cells to regulatory cells through
the generation of a non-immunosuppressive microenvironment
(Figure 2B). Regardless, both of these models suggest that the
goal of antigen-specific immunotherapies is not simply to gen-
erate effector responses, but rather to tip the balance between
antigen-specific effector and regulatory responses toward produc-
tive anti-tumor immunity. Further research into these antigen-
specific populations, how they are affected by antigen-specific
vaccination, how they affect the generation of antigen-specific
effector immune responses, and whether they have any predic-
tive value toward the ultimate efficacy of anti-tumor vaccines,
remains to be elucidated. While CD8+ Tregs are not as well stud-
ied as their CD4+ Treg counterparts, both CD8+ nTreg and iTreg
have been identified and characterized, including reports in indi-
viduals with cancer (50). In our published studies, the reliance
of PAP-specific CD8+CTLA-4+ T cells on IL-35 for mediating
contact-independent suppression (with no identifiable role played
by IL-10 nor TGF-β) suggests that these cells may be more akin to
a population of CD8+ iTr35 cells which are dependent on IL-
35 for contact-independent suppressive activity, as opposed to
nTreg which are able to utilize multiple mechanisms of contact-
independent suppression. Furthermore, our observation that the
suppressive function of IL-35-expressing CD8+CTLA-4+ Treg
is temporally regulated following antigen-specific immunization
suggests that this population may be able to be modulated depend-
ing on the tumor microenvironment. However,additional research
is required to determine how antigen-specific IL-35-expressing
Treg are affected by antigen-specific immunization, as well as
how these IL-35+ Treg responses are generated in tumor-bearing
individuals.
To better characterize the generation and fate of iTr35 cells, it
will be important to shed light onto the mechanisms that regulate
the expression of IL-35 by Tregs. It is clear that expression of IL-35
by nTreg and iTreg requires activation, whether through inflam-
matory responses, non-specific stimulation of the T-cell receptor,
or through encounter of antigen by antigen-specific Tregs (19, 22,
23). Additionally, it appears that Foxp3 does not directly play a role
in the regulation of IL-35 expression, providing further evidence
that IL-35 serves primarily as a potent mediator of suppression in
induced regulatory populations rather than Foxp3+ nTregs (59).
However, the regulation of Foxp3 does potentially open up new
avenues of potential means of IL-35 regulation. Foxp3, along with
other factors associated with Tregs such as CTLA-4, are specifically
hypomethylated in nTreg cells, resulting in increased access to the
transcriptional complex and higher expression levels compared
to T conv cells, where these sequences are preferentially hyperme-
thylated (60, 61). Additionally, the expression of various cytokines
has been shown to be epigenetically regulated, including IL-10 and
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FIGURE 2 |The effects of natural versus induced PAP-specific CD8+Tregs
pre-immunization, post-immunization, and in long-term follow up. (A) If
the observed PAP-specific CD8+CTLA-4+T cells represent a population of
natural Tregs, pre-immunization samples (left panels) have PAP-specific CD8+
nTregs present (red cells) that utilize IL-35 to suppress the activity of
PAP-specific effector cells (dark green) both in the periphery (top panels) as
well as in the tumor microenvironment (bottom panels), as well as the ability
to induce a population of IL-35-expressing Tregs (light green). Administration of
a DNA vaccine encoding PAP leads to the presentation of PAP-derived
epitopes on the surface of APCs immediately post-immunization (center
panels), leading to the expansion of antigen-specific effector cells. However,
these cells are in small numbers, and when they traffic to the tumor site, they
are outnumbered by PAP-specific nTreg that are able to suppress their
proliferation and effector functions. It is not until long-term follow up when
these effector responses are able to outnumber antigen-specific nTreg,
leading to the generation of productive anti-tumor immunity. (B) In a model
where CD8+CTLA-4+T cells represent a population of novel CD8+ iTr35 cells
(light green cells), these iTregs would be able to convert effector cells (dark
green) into additional iTreg through their expression of IL-35, thus propagating
infectious tolerance to prevent the generation of productive anti-tumor
immunity both pre-immunization as well as immediately post-immunization.
This process would be predicted to continue until long-term follow up, when
antigen-specific effectors could expand to a sufficient level to outnumber
these iTreg responses, and potentially prevent the generation of induced
antigen-specific Treg by promoting tumor destruction and a non-suppressive
tumor microenvironment.
TGF-β, which can in turn induce epigenetic changes that can lead
to the generation of iTreg populations (62–65). This raises the pos-
sibility that the induction of IL-35 expression in iTr35 cells may be
epigenetically regulated, which would permit the heritable trans-
mission of IL-35 expression into subsequent progeny iTr35 cells
while maintaining flexibility for altered expression levels based
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on the immune profile of the microenvironment. To date, epi-
genetic regulation of IL-35 expression has not been specifically
evaluated – however, regions of the IL-12p35 promoter have been
shown to become methylated to regulate IL-12 expression by DCs
(66) and IL-12p35 intronic regions can become demethylated in
non-activated Tregs (65). Additionally, the IL-12Rβ2 receptor has
also been shown to be epigenetically regulated (67), suggesting
that IL-35 could also be regulated using an epigenetic mechanism.
Many challenges also remain regarding the various populations
of induced regulatory cells, and how these populations comple-
ment each other. Clearly there is a role for IL-10 in the generation
of iTr35 cells, though the converse does not appear to be true,
with IL-35 not appearing to play a central role in the genera-
tion of IL-10-secreting Tr1 or TGF-β-secreting Th3 populations.
This may suggest that these populations may have distinct roles
in the suppression of inflammatory immune responses. Alter-
natively, this could be a reflection of the redundancy of the
immune system, having multiple layers of regulatory popula-
tions that can mediate similar effects, but that perhaps iTr35
cells represent more of a terminally differentiated regulatory cell
that is mobilized when high levels of immunosuppression are
required. While studying the differentiation pattern of this pop-
ulation raises significant experimental challenges, these studies
will be essential to better understand the nature of T-cell func-
tional plasticity, as well as how IL-35-expression fits into this
process. Doing so will allow for the identification of methods
that can be used to control and guide these regulatory responses
to design effective therapies for cancer, autoimmunity, and tissue
transplantation.
ACKNOWLEDGMENTS
This work was supported for Brian M. Olson by the NIH (R01
CA142608), by the US Army Medical Research and Materiel
Command Prostate Cancer Research Program (W81XWH-11-1-
0196), and by the University of Wisconsin Carbone Cancer Center.
William J. Burlingham and Jeremy A. Sullivan are supported by the
NIH (PO1AI084853, R01-AI066219) and by the EU-sponsored
One Study (William J. Burlingham).
REFERENCES
1. Heusinkveld M, van der Burg SH.
Identification and manipulation
of tumor associated macrophages
in human cancers. J Transl Med
(2011) 9:216. doi:10.1186/1479-
5876-9-216
2. Nishizuka Y, Sakakura T. Thy-
mus and reproduction: sex-linked
dysgenesia of the gonad after
neonatal thymectomy in mice. Sci-
ence (1969) 166:753–5. doi:10.1126/
science.166.3906.753
3. Gershon RK, Kondo K. Cell
interactions in the induction
of tolerance: the role of thymic
lymphocytes. Immunology (1970)
18:723–37.
4. Gershon RK, Kondo K. Infec-
tious immunological tolerance.
Immunology (1971) 21:903–14.
5. Cantor H, Hugenberger J, Mcvay-
Boudreau L, Eardley DD, Kemp
J, Shen FW, et al. Immunoregu-
latory circuits among T-cell sets.
Identification of a subpopulation
of T-helper cells that induces feed-
back inhibition. J Exp Med (1978)
148:871–7. doi:10.1084/jem.148.4.
871
6. Sakaguchi S, Sakaguchi N, Asano
M, Itoh M, Toda M. Immunologic
self-tolerance maintained by acti-
vated T cells expressing IL-2 recep-
tor alpha-chains (CD25). Break-
down of a single mechanism of self-
tolerance causes various autoim-
mune diseases. J Immunol (1995)
155:1151–64.
7. Roncarolo MG, Bacchetta R, Bor-
dignon C, Narula S, Levings MK.
Type 1 T regulatory cells. Immunol
Rev (2001) 182:68–79. doi:10.1034/
j.1600-065X.2001.1820105.x
8. Weiner HL. Induction and mech-
anism of action of transforming
growth factor-beta-secreting Th3
regulatory cells. Immunol Rev
(2001) 182:207–14. doi:10.1034/j.
1600-065X.2001.1820117.x
9. Collison LW, Workman CJ, Kuo TT,
Boyd K, Wang Y, Vignali KM, et al.
The inhibitory cytokine IL-35 con-
tributes to regulatory T-cell func-
tion. Nature (2007) 450:566–9. doi:
10.1038/nature06306
10. Vignali DA, Kuchroo VK. IL-12
family cytokines: immunological
playmakers. Nat Immunol (2012)
13:722–8. doi:10.1038/ni.2366
11. Del Vecchio M, Bajetta E, Canova S,
Lotze MT, Wesa A, Parmiani G, et
al. Interleukin-12: biological prop-
erties and clinical application. Clin
Cancer Res (2007) 13:4677–85. doi:
10.1158/1078-0432.CCR-07-0776
12. Natarajan C, Bright JJ. Curcumin
inhibits experimental allergic
encephalomyelitis by blocking
IL-12 signaling through Janus
kinase-STAT pathway in T lym-
phocytes. J Immunol (2002)
168:6506–13.
13. Mondal S, Roy A, Pahan K.
Functional blocking mono-
clonal antibodies against IL-
12p40 homodimer inhibit adop-
tive transfer of experimental
allergic encephalomyelitis. J
Immunol (2009) 182:5013–23.
doi:10.4049/jimmunol.0801734
14. Croxford AL, Mair F, Becher B.
IL-23: one cytokine in control
of autoimmunity. Eur J Immunol
(2012) 42:2263–73. doi:10.1002/eji.
201242598
15. Hunter CA, Kastelein R.
Interleukin-27: balancing protective
and pathological immunity.
Immunity (2012) 37:960–9.
doi:10.1016/j.immuni.2012.11.003
16. Niedbala W, Wei XQ, Cai B, Hueber
AJ,Leung BP,Mcinnes IB,et al. IL-35
is a novel cytokine with therapeu-
tic effects against collagen-induced
arthritis through the expansion of
regulatory T cells and suppres-
sion of Th17 cells. Eur J Immunol
(2007) 37:3021–9. doi:10.1002/eji.
200790047
17. Devergne O, Birkenbach M, Kieff E.
Epstein-Barr virus-induced gene 3
and the p35 subunit of interleukin
12 form a novel heterodimeric
hematopoietin. Proc Natl Acad Sci U
S A (1997) 94:12041–6. doi:10.1073/
pnas.94.22.12041
18. Jones LL, Chaturvedi V, Uyttenhove
C, Van Snick J, Vignali DA. Distinct
subunit pairing criteria within the
heterodimeric IL-12 cytokine fam-
ily. Mol Immunol (2012) 51:234–44.
doi:10.1016/j.molimm.2012.03.025
19. Chaturvedi V, Collison LW, Guy
CS, Workman CJ, Vignali DA. Cut-
ting edge: human regulatory T cells
require IL-35 to mediate suppres-
sion and infectious tolerance. J
Immunol (2011) 186:6661–6. doi:
10.4049/jimmunol.1100315
20. Kaser T, Mullebner A, Hartl RT,
Essler SE, Saalmuller A, Catharina
Duvigneau J. Porcine T-helper and
regulatory T cells exhibit versatile
mRNA expression capabilities for
cytokines and co-stimulatory mol-
ecules. Cytokine (2012) 60:400–9.
doi:10.1016/j.cyto.2012.07.007
21. Bardel E, Larousserie F, Charlot-
Rabiega P, Coulomb-L’Hermine
A, Devergne O. Human CD4+
CD25+ Foxp3+ regulatory
T cells do not constitutively
express IL-35. J Immunol (2008)
181:6898–905.
22. Collison LW, Chaturvedi V, Hen-
derson AL, Giacomin PR, Guy C,
Bankoti J, et al. IL-35-mediated
induction of a potent regulatory
T cell population. Nat Immunol
(2010) 11:1093–101. doi:10.1038/
ni.1952
23. Olson BM, Jankowska-Gan E,
Becker JT, Vignali DA, Burlingham
WJ, Mcneel DG. Human prostate
tumor antigen-specific CD8+
regulatory T cells are inhibited
by CTLA-4 or IL-35 blockade. J
Immunol (2012) 189:5590–601.
doi:10.4049/jimmunol.1201744
24. Long J, Zhang X,Wen M, Kong Q, Lv
Z, An Y, et al. IL-35 over-expression
increases apoptosis sensitivity and
suppresses cell growth in human
cancer cells. Biochem Biophys Res
Commun (2013) 430:364–9. doi:10.
1016/j.bbrc.2012.11.004
25. Wang Z, Liu JQ, Liu Z, Shen R,
Zhang G, Xu J, et al. Tumor-derived
IL-35 promotes tumor growth by
enhancing myeloid cell accumula-
tion and angiogenesis. J Immunol
(2013) 190:2415–23. doi:10.4049/
jimmunol.1202535
26. Li X, Mai J, Virtue A, Yin Y,
Gong R, Sha X, et al. IL-35 is a
novel responsive anti-inflammatory
cytokine – a new system of catego-
rizing anti-inflammatory cytokines.
PLoS One (2012) 7:e33628. doi:10.
1371/journal.pone.0033628
27. Collison LW, Vignali DA.
Interleukin-35: odd one out or
part of the family? Immunol Rev
(2008) 226:248–62. doi:10.1111/j.
1600-065X.2008.00704.x
Frontiers in Immunology | Immunological Tolerance October 2013 | Volume 4 | Article 315 | 10
Olson et al. Propagation of infectious tolerance by IL-35
28. Collison LW, Delgoffe GM, Guy CS,
Vignali KM, Chaturvedi V, Fair-
weather D, et al. The composi-
tion and signaling of the IL-35
receptor are unconventional. Nat
Immunol (2012) 13:290–9. doi:10.
1038/ni.2227
29. Saito M, Yoshida K, Hibi M,
Taga T, Kishimoto T. Molecular
cloning of a murine IL-6 receptor-
associated signal transducer,
gp130, and its regulated expres-
sion in vivo. J Immunol (1992)
148:4066–71.
30. Trinchieri G. Interleukin-12 and
the regulation of innate resistance
and adaptive immunity. Nat Rev
Immunol (2003) 3:133–46. doi:10.
1038/nri1001
31. Langhans B, Braunschweiger I,
Arndt S, Schulte W, Satoguina J, Lay-
land LE, et al. Core-specific adap-
tive regulatory T-cells in different
outcomes of hepatitis C. Clin Sci
(Lond) (2010) 119:97–109. doi:10.
1042/CS20090661
32. Liu JQ, Liu Z, Zhang X, Shi Y,
Talebian F, Carl JW Jr, et al.
Increased Th17 and regulatory T
cell responses in EBV-induced gene
3-deficient mice lead to marginally
enhanced development of autoim-
mune encephalomyelitis. J Immunol
(2012) 188:3099–106. doi:10.4049/
jimmunol.1100106
33. Tirotta E, Duncker P, Oak J,
Klaus S, Tsukamoto MR, Gov L,
et al. Epstein-Barr virus-induced
gene 3 negatively regulates neu-
roinflammation and T cell activa-
tion following coronavirus-induced
encephalomyelitis. J Neuroimmunol
(2013) 254:110–6. doi:10.1016/j.
jneuroim.2012.10.005
34. Kochetkova I, Golden S, Holder-
ness K, Callis G, Pascual DW. IL-
35 stimulation of CD39+ regulatory
T cells confers protection against
collagen II-induced arthritis via the
production of IL-10. J Immunol
(2010) 184:7144–53. doi:10.4049/
jimmunol.0902739
35. Wirtz S, Billmeier U, Mchedlidze
T, Blumberg RS, Neurath
MF. Interleukin-35 mediates
mucosal immune responses
that protect against T-cell-
dependent colitis. Gastroen-
terology (2011) 141:1875–86.
doi:10.1053/j.gastro.2011.07.040
36. Tong H, Miyazaki Y, Yamazaki
M, Hara H, Waldmann H,
Hori S, et al. Exacerbation
of delayed-type hypersensitiv-
ity responses in EBV-induced
gene-3 (EBI-3)-deficient mice.
Immunol Lett (2010) 128:108–15.
doi:10.1016/j.imlet.2010.01.001
37. Whitehead GS, Wilson RH, Nakano
K, Burch LH, Nakano H, Cook DN.
IL-35 production by inducible cos-
timulator (ICOS)-positive regula-
tory T cells reverses established IL-
17-dependent allergic airways dis-
ease. J Allergy Clin Immunol (2012)
129(207–215):e201–5. doi:10.1016/
j.jaci.2011.08.009
38. Tsuda M, Zhang W, Yang GX,
Tsuneyama K, Ando Y, Kawata
K, et al. Deletion of interleukin
(IL)-12p35 induces liver fibro-
sis in dominant-negative TGFbeta
receptor type II mice. Hepatology
(2013) 57:806–16. doi:10.1002/hep.
25829
39. Wu H, Li P, Shao N, Ma J, Ji M,
Sun X, et al. Aberrant expression
of Treg-associated cytokine IL-35
along with IL-10 and TGF-beta in
acute myeloid leukemia. Oncol Lett
(2012) 3:1119–23. doi:10.3892/ol.
2012.614
40. Nishino R, Takano A, Oshita H,
Ishikawa N, Akiyama H, Ito H, et
al. Identification of Epstein-Barr
virus-induced gene 3 as a novel
serum and tissue biomarker and a
therapeutic target for lung cancer.
Clin Cancer Res (2011) 17:6272–86.
doi:10.1158/1078-0432.CCR-11-
0060
41. Lin Y, Huang Y, Lu Z, Luo C,
Shi Y, Zeng Q, et al. Decreased
plasma IL-35 levels are related to
the left ventricular ejection fraction
in coronary artery diseases. PLoS
One (2011) 7:e52490. doi:10.1371/
journal.pone.0052490
42. Bai J, Qiu SL, Zhong XN, Huang
QP, He ZY, Zhang JQ, et al. Ery-
thromycin enhances CD4+Foxp3+
regulatory T-cell responses in a
rat model of smoke-induced lung
inflammation. Mediators Inflamm
(2012) 2012:410232. doi:10.1155/
2012/410232
43. Huang CH, Loo EX, Kuo IC,
Soh GH, Goh DL, Lee BW, et
al. Airway inflammation and IgE
production induced by dust mite
allergen-specific memory/effector
Th2 cell line can be effectively
attenuated by IL-35. J Immunol
(2011) 187:462–71. doi:10.4049/
jimmunol.1100259
44. Bettini M, Castellaw AH, Lennon
GP, Burton AR, Vignali DA. Pre-
vention of autoimmune diabetes by
ectopic pancreatic beta-cell expres-
sion of interleukin-35. Diabetes
(2012) 61:1519–26. doi:10.2337/
db11-0784
45. Kuo J, Nardelli DT, Warner
TF, Callister SM, Schell RF.
Interleukin-35 enhances Lyme
arthritis in Borrelia-vaccinated
and -infected mice. Clin Vaccine
Immunol (2011) 18:1125–32.
doi:10.1128/CVI.00052-11
46. Benjamin RJ, Waldmann H. Induc-
tion of tolerance by monoclonal
antibody therapy. Nature (1986)
320:449–51. doi:10.1038/320449a0
47. Qin S, Cobbold SP, Pope H, Elliott
J, Kioussis D, Davies J, et al.
“Infectious” transplantation toler-
ance. Science (1993) 259:974–7. doi:
10.1126/science.8094901
48. Gravano DM,Vignali DA. The battle
against immunopathology: infec-
tious tolerance mediated by regula-
tory T cells. Cell Mol Life Sci (2012)
69:1997–2008. doi:10.1007/s00018-
011-0907-z
49. Collison LW, Pillai MR, Chaturvedi
V, Vignali DA. Regulatory T cell
suppression is potentiated by tar-
get T cells in a cell contact, IL-
35- and IL-10-dependent manner.
J Immunol (2009) 182:6121–8. doi:
10.4049/jimmunol.0803646
50. Mougiakakos D, Choudhury A,
Lladser A, Kiessling R, Johansson
CC. Regulatory T cells in cancer. Adv
Cancer Res (2010) 107:57–117. doi:
10.1016/S0065-230X(10)07003-X
51. Shafer-Weaver KA, Anderson MJ,
Stagliano K, Malyguine A, Green-
berg NM, Hurwitz AA. Cutting
edge: tumor-specific CD8+ T cells
infiltrating prostatic tumors are
induced to become suppressor cells.
J Immunol (2009) 183:4848–52. doi:
10.4049/jimmunol.0900848
52. Whiteside TL, Schuler P, Schilling B.
Induced and natural regulatory T
cells in human cancer. Expert Opin
Biol Ther (2012) 12:1383–97. doi:
10.1517/14712598.2012.707184
53. Bergmann C, Strauss L, Zei-
dler R, Lang S, Whiteside TL.
Expansion of human T regulatory
type 1 cells in the microenviron-
ment of cyclooxygenase 2 over-
expressing head and neck squa-
mous cell carcinoma. Cancer Res
(2007) 67:8865–73. doi:10.1158/
0008-5472.CAN-07-0767
54. Mandapathil M, Szczepanski MJ,
Szajnik M, Ren J, Lenzner DE, Jack-
son EK, et al. Increased ectonu-
cleotidase expression and activity in
regulatory T cells of patients with
head and neck cancer. Clin Can-
cer Res (2009) 15:6348–57. doi:10.
1158/1078-0432.CCR-09-1143
55. Mandapathil M, Whiteside TL. Tar-
geting human inducible regula-
tory T cells (Tr1) in patients
with cancer: blocking of adenosine-
prostaglandin E(2) cooperation.
Expert Opin Biol Ther (2011)
11:1203–14. doi:10.1517/14712598.
2011.581225
56. Pillai MR, Collison LW, Wang X,
Finkelstein D, Rehg JE, Boyd K,
et al. The plasticity of regula-
tory T cell function. J Immunol
(2011) 187:4987–97. doi:10.4049/
jimmunol.1102173
57. Elkord E, Sharma S, Burt DJ,
Hawkins RE. Expanded subpop-
ulation of FoxP3+ T regulatory
cells in renal cell carcinoma co-
express Helios, indicating they
could be derived from natural but
not induced Tregs. Clin Immunol
(2011) 140:218–22. doi:10.1016/j.
clim.2011.04.014
58. Gottschalk RA, Corse E, Allison
JP. Expression of Helios in periph-
erally induced Foxp3+ regulatory
T cells. J Immunol (2012) 188:
976–80. doi:10.4049/jimmunol.
1102964
59. Allan SE, Song-Zhao GX, Abra-
ham T, Mcmurchy AN, Lev-
ings MK. Inducible reprogram-
ming of human T cells into Treg
cells by a conditionally active
form of FOXP3. Eur J Immunol
(2008) 38:3282–9. doi:10.1002/eji.
200838373
60. Lal G, Bromberg JS. Epigenetic
mechanisms of regulation of
Foxp3 expression. Blood (2009)
114:3727–35. doi:10.1182/blood-
2009-05-219584
61. Ohkura N, Hamaguchi M,
Morikawa H, Sugimura K, Tanaka
A, Ito Y, et al. T cell receptor
stimulation-induced epigenetic
changes and Foxp3 expression
are independent and complemen-
tary events required for Treg cell
development. Immunity (2012) 37:
785–99. doi:10.1016/j.immuni.
2012.09.010
62. Lee CG, Sahoo A, Im SH. Epigenetic
regulation of cytokine gene expres-
sion in T lymphocytes. Yonsei Med J
(2009) 50:322–30. doi:10.3349/ymj.
2009.50.3.322
63. Saraiva M, O’Garra A. The
regulation of IL-10 produc-
tion by immune cells. Nat Rev
Immunol (2010) 10:170–81.
doi:10.1038/nri2711
64. Matsumura N, Huang Z, Mori S,
Baba T, Fujii S, Konishi I, et al. Epi-
genetic suppression of the TGF-beta
pathway revealed by transcriptome
profiling in ovarian cancer. Genome
Res (2011) 21:74–82. doi:10.1101/
gr.108803.110
65. Ohkura N, Kitagawa Y, Sakaguchi
S. Development and maintenance
of regulatory T cells. Immunity
(2013) 38:414–23. doi:10.1016/j.
immuni.2013.03.002
66. Oliva J, French SW. Changes in
IL12A methylation pattern in livers
www.frontiersin.org October 2013 | Volume 4 | Article 315 | 11
Olson et al. Propagation of infectious tolerance by IL-35
from mice fed DDC. Exp Mol
Pathol (2012) 92:191–3. doi:10.
1016/j.yexmp.2012.01.001
67. Suzuki M, Iizasa T, Nakajima T,
Kubo R, Iyoda A, Hiroshima K,
et al. Aberrant methylation of
IL-12Rbeta2 gene in lung adeno-
carcinoma cells is associated with
unfavorable prognosis. Ann Surg
Oncol (2007) 14:2636–42. doi:10.
1245/s10434-006-9310-7
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 13 June 2013; paper pending
published: 26 July 2013; accepted: 18 Sep-
tember 2013; published online: 18 Octo-
ber 2013.
Citation: Olson BM, Sullivan JA and
Burlingham WJ (2013) Interleukin 35:
a key mediator of suppression and
the propagation of infectious toler-
ance. Front. Immunol. 4:315. doi:
10.3389/fimmu.2013.00315
This article was submitted to Immuno-
logical Tolerance, a section of the journal
Frontiers in Immunology.
Copyright © 2013 Olson, Sullivan and
Burlingham. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or repro-
duction in other forums is permitted, pro-
vided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
Frontiers in Immunology | Immunological Tolerance October 2013 | Volume 4 | Article 315 | 12
